País: Regne Unit
Idioma: anglès
Font: MHRA (Medicines & Healthcare Products Regulatory Agency)
Nevirapine
Boehringer Ingelheim Ltd
J05AG01
Nevirapine
50mg
Modified-release tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: ; GTIN: 5012816050150
1 PACKAGE LEAFLET: INFORMATION FOR THE USER VIRAMUNE 100 MG PROLONGED-RELEASE TABLETS nevirapine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have further questions, please ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Viramune is and what it is used for 2. What do you need to know before you take Viramune 3. How to take Viramune 4. Possible side effects 5. How to store Viramune 6. Contents of the pack and other information 1. WHAT VIRAMUNE IS AND WHAT IT IS USED FOR Viramune belongs to a group of medicines called antiretrovirals, used in the treatment of Human Immunodeficiency Virus (HIV-1) infection. The active substance of your medicine is called nevirapine. Nevirapine belongs to a class of anti-HIV medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs). Reverse transcriptase is an enzyme that HIV needs in order to multiply. Nevirapine stops reverse transcriptase from working. By stopping reverse transcriptase from working, Viramune helps control HIV-1 infection. Viramune is indicated for the treatment of HIV-1 infected adolescents and children three years and above and able to swallow tablets. You must take Viramune together with other antiretroviral medicines. Your doctor will recommend the best medicines for you. Viramune prolonged-release tablets should only be used after a two-week treatment with another type of Viramune (immediate-release tablets or suspension) unless you are currently on Viramune and are switching to the prolonged-release form. IF VIRAMUNE HAS BEEN PRESCRIBED FOR YOUR CHILD, PLEASE NOTE THAT ALL INFORMATION IN THIS LEAFL Llegiu el document complet